Order Careers Contact Us Sign in Adaptive Biotechnologies Order Careers
Contact Us Sign in Immune Profiling Platform Platform OverviewPublications
Products & Services LIFE SCIENCES RESEARCHimmunoSEQ®CLINICAL
DIAGNOSTICSclonoSEQ®PipelineDRUG DISCOVERYCellular TherapyVaccines
PARTNERSHIPS Cancer Cellular TherapyAntigen MapBiopharma PartnershipsStrategic
Collaborators About Us Our StoryCultureCareersNewsroomContact Us Adaptive
Biotechnologies to Present at the 37th Annual J.P. Morgan Healthcare
Conference 01/03/2019 SEATTLE, Wa., January 3, 2019 – Adaptive Biotechnologies
today announced that Chad Robins, chief executive officer and co-founder, will
present at the 37th Annual J.P. Morgan Healthcare Conference on January 8,
2019 at 11:30 am PT (2:30 pm ET) in San Francisco. Robins will also
participate in a panel presentation, Reinventing the Disease Continuum Through
Precision Health, on January 7, 2019 at 5:00 pm PT (8:00 pm ET) to discuss the
impact of immune profiling on the future of immune-driven medicine. A live
webcast of the presentation and Q&A; session can be accessed from the Newsroom
under Events on the Adaptive website at adaptivebiotech.com. Following the
live presentation, a replay of the webcast will be available on the Company’s
website for 90 days. About Adaptive Biotechnologies Adaptive Biotechnologies
is a pioneer and leader in immune-driven medicine that aims to improve
people’s lives by learning from the wisdom of their adaptive immune systems.
Adaptive’s proprietary immune profiling platform reveals and translates
insights from our adaptive immune systems with unprecedented scale and
precision. Working with drug developers, clinicians and academic researchers,
we are applying these insights to develop products that will transform the way
we diagnose and treat diseases such as cancer, autoimmune conditions, and
infectious diseases. For more information, please visit adaptivebiotech.com.
CONTACT: Adaptive Biotechnologies Beth Keshishian (media) 917-912-7195
media@adaptivebiotech.com Previous Press Release Adaptive Biotechnologies and
Collaborators to Present 28 Studies at ASH 2018 That Support the Use of the
clonoSEQ® Assay to Detect and Monitor Minimal Residual Disease in Patients
with Blood Cancers 12/01/2018 Next Press Release Adaptive Biotechnologies to
Enter Into Worldwide Collaboration and License Agreement with Genentech to
Develop Personalized Cellular Therapies for the Treatment of Cancer 01/04/2019
Corporate/Research (855) 466-8667 Diagnostics (888) 522-8988 Immune Profiling
PlatformPlatform Overview Publications Products & ServicesLIFE SCIENCES
RESEARCH immunoSEQ® CLINICAL DIAGNOSTICS clonoSEQ® Pipeline DRUG DISCOVERY
Cellular Therapy Vaccines PartnershipsCancer Cellular Therapy Antigen Map
Biopharma Partnerships Strategic Collaborators About UsOur Story Culture
Careers News & Events Contact Us © Adaptive Biotechnologies. All Rights
Reserved. Terms of Use Online Privacy Policy Privacy Shield Policy HIPAA
Policy Code of Conduct Patents & Trademarks Licenses